CRP /albumin Ratio and Neutrophil Lymphocyte Ratio in Predicting Activity in IBD Patients
CRP/ Albumin Ratio and Neutrophil Lymphocyte Ratio in Predicting Activity in IBD Patients
1 other identifier
observational
35
1 country
2
Brief Summary
This study aimed to assess the clinical utility of the NLR (neutrophil lymphocyte ratio) and CRP Albumin ratio in predicting activity of IBD Patients in assiut university
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2025
Shorter than P25 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 20, 2024
CompletedFirst Posted
Study publicly available on registry
December 27, 2024
CompletedStudy Start
First participant enrolled
January 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2025
CompletedDecember 27, 2024
September 1, 2024
9 months
September 20, 2024
December 24, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
C-reactive protein /albumin ratio and neutrophil lymphocyte ratio in predicting activity in Inflammatory Bowel Disease Patients
Neutrophil lymphocyte ratio and CRP/Albumin ratio in detecting activity in IBD Patients.
1 years
Eligibility Criteria
Pt more than 18 years not DM not cardiac failure Not Liver failure No malignancy
You may qualify if:
- Patients more than 18 years newly diagnosed as IBD
You may not qualify if:
- Patients Not DM Not cardiac failure Not Liver failure No malignancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Assiut University
Asyut, Egypt
Assiut university hospital
Egypt, Assiut, Egypt
Related Publications (4)
Torun S, Tunc BD, Suvak B, Yildiz H, Tas A, Sayilir A, Ozderin YO, Beyazit Y, Kayacetin E. Assessment of neutrophil-lymphocyte ratio in ulcerative colitis: a promising marker in predicting disease severity. Clin Res Hepatol Gastroenterol. 2012 Oct;36(5):491-7. doi: 10.1016/j.clinre.2012.06.004. Epub 2012 Jul 27.
PMID: 22841412BACKGROUNDNguyen AL, Brick C, Liu D, Gibson DJ, Gibson PR, Sparrow MP. Clinical utility of C-reactive protein-to-albumin ratio in the management of patients with inflammatory bowel disease. JGH Open. 2024 Apr 15;8(4):e13059. doi: 10.1002/jgh3.13059. eCollection 2024 Apr.
PMID: 38623491BACKGROUNDDemir AK, Demirtas A, Kaya SU, Tastan I, Butun I, Sagcan M, Sahin S, Tasliyurt T, Yilmaz A. The relationship between the neutrophil-lymphocyte ratio and disease activity in patients with ulcerative colitis. Kaohsiung J Med Sci. 2015 Nov;31(11):585-90. doi: 10.1016/j.kjms.2015.10.001. Epub 2015 Oct 31.
PMID: 26678939BACKGROUNDLangley BO, Guedry SE, Goldenberg JZ, Hanes DA, Beardsley JA, Ryan JJ. Inflammatory Bowel Disease and Neutrophil-Lymphocyte Ratio: A Systematic Scoping Review. J Clin Med. 2021 Sep 17;10(18):4219. doi: 10.3390/jcm10184219.
PMID: 34575330BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Lecturer
Study Record Dates
First Submitted
September 20, 2024
First Posted
December 27, 2024
Study Start
January 1, 2025
Primary Completion
October 1, 2025
Study Completion
December 1, 2025
Last Updated
December 27, 2024
Record last verified: 2024-09